Physician profile
Peter K Sand
NPI 1700984408
$184,873.47
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $17K · 2021: $20K · 2022: $21K · 2023: $100K · 2024: $6,825.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $103K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,275 · Travel and Lodging: $1,058.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $103,251.49 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,275.00 |
| Travel and Lodging | $1,058.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Valencia Technologies Corporation | $94,337.00 | 2023 | Ecoin Device Kit |
| Urovant Sciences INC | $26,914.82 | 2021-2022 | |
| Allergan, INC. | $25,487.50 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $12,247.67 | 2023-2024 | Gemtesa |
| Ferring Pharmaceuticals INC. | $7,859.52 | 2019 | |
| Abbvie INC. | $7,272.61 | 2022 | |
| Antares Pharma, INC. | $4,514.69 | 2020-2021 | |
| Hologic Sales and Service, LLC | $4,367.21 | 2020 | |
| Jazz Pharmaceuticals INC. | $1,718.75 | 2020 | |
| Laborie Medical Technologies Corp. | $112.10 | 2019 | |
| Convatec INC. | $25.52 | 2022 | |
| Axonics, INC. | $16.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Sand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.